论文部分内容阅读
目的:探讨他汀类药物应用在慢性肾病患者治疗中的安全性。方法:选取2014年3月至2015年3月该院收治的慢性肾病患者76例作为本次研究的对象,将患者随机分成对照组和研究组各38例,对照组予以常规治疗,研究组在此基础上应用他汀类药物治疗。结果:研究组治疗后TC、TG、尿酸以及24 h尿蛋白要显著优于对照组(P<0.05);两组不良反应发生情况对比无显著差异(P>0.05)。结论:慢性肾病患者应用他汀类药物治疗,可以明显降低血脂与尿蛋白水平,有效保护肾脏,且不良反应少,安全可行,值得在临床上大力推广。
Objective: To investigate the safety of statins in the treatment of patients with chronic kidney disease. Methods: From March 2014 to March 2015, 76 patients with chronic kidney disease admitted to our hospital were selected as the object of this study. Patients were randomly divided into control group and study group, with 38 cases in each group. The control group was treated routinely. Based on this statin therapy. Results: The TC, TG, uric acid and 24 h urinary protein in the study group were significantly better than those in the control group (P <0.05). There was no significant difference in adverse reaction between the two groups (P> 0.05). Conclusion: Statin therapy in patients with chronic kidney disease can significantly reduce blood lipids and urine protein levels, effectively protect the kidneys, and less adverse reactions, safe and feasible, it is worth to clinically promote.